Trade Summary

1 week ago, Struthers Richard Scott, serving as Pres, CEO at Crinetics Pharmaceuticals, Inc. (CRNX), sold 21,981 shares at $37.37 per share, for a total transaction value of $821,513.00. Following this transaction, Struthers Richard Scott now holds 1,382,983 shares of CRNX.

This sale represents a 2.00% decrease in Struthers Richard Scott's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 18, 2026, 2 days after the trade was made.

Crinetics Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.